Total Revenue was US$3.6 million for the first quarter FY2022, an increase of US$2.3 million on the comparative quarter due to growth in royalties and US$1.2 million of milestone revenue given Takeda received approval to manufacture and market Alofisel® (darvadstrocel) in Japan for the treatment of complex perianal fistulas in patients with non-active or mildly active luminal Crohn’s Disease.”
Going in the right direction , one positive announcement will unlock the valuation for this . Dirt cheap at these rates
Total Revenue was US$3.6 million for the first quarter FY2022,...
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
92.0¢ |
Change
-0.005(0.54%) |
Mkt cap ! $1.050B | |||
| Open | High | Low | Value | Volume |
| 92.0¢ | 92.5¢ | 91.5¢ | $1.133M | 1.233M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 151980 | 91.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 92.0¢ | 29989 | 2 |
View Market Depth
| Last trade - 16.10pm 18/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |